Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kuros Biosciences AG (KURN) CHF1

Sell:2.55 CHF Buy:2.49 CHF Change: 0.11 CHF (4.62%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
Sell:2.55 CHF
Buy:2.49 CHF
Change: 0.11 CHF (4.62%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
Sell:2.55 CHF
Buy:2.49 CHF
Change: 0.11 CHF (4.62%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Contact details

Address:
Wagistrasse 25
SCHLIEREN
8952
Switzerland
Telephone:
+41 (44) 7334747
Website:
www.kuros.ch/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KURN
ISIN:
CH0325814116
Market cap:
53.35 million CHF
Shares in issue:
22.40 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Clemens van Blitterswijk
    Chairman of the Board of Directors
  • Joost de Bruijn
    Chief Executive Officer, Member of the Board of Directors
  • Leanna Caron
    Vice Chairman of the Board of Directors
  • Michael Grau
    Chief Financial Officer
  • Jason Schense
    Chief Technology Officer, Member of the Executive Board
  • Alistair Irvine
    Member of the Management Board, Chief Business Officer
  • Pascal Longlade
    Chief Medical Officer, Member of the Management Board
  • Philippe Saudan
    Chief Development Officer, Member of the Executive Board
  • Frank-Jan van der Velden
    Member of the Executive Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.